Objective:
To discuss the relationship between ocular surface disease (OSD) and glaucoma, and explore specific alternatives to glaucoma drops that cause OSD.
Key Findings:
- Glaucoma patients have a higher prevalence of OSD, often exacerbated by topical therapies.
- BAK is a significant contributor to OSD due to its damaging effects on conjunctival goblet cells.
- There are now more preservative-free options available for glaucoma treatment.
- Demographics of OSD and glaucoma overlap, being more common in older individuals and postmenopausal females.
Interpretation:
Ophthalmologists should be proactive in addressing OSD in glaucoma patients, utilizing alternative therapies and preventive measures to enhance patient quality of life, and actively screening for symptoms.
Limitations:
- Insurance coverage for preservative-free options may be limited.
- Not all glaucoma patients may have access to compounding pharmacies for custom formulations.
- There may be a lack of awareness among ophthalmologists regarding the prevalence of OSD in glaucoma patients.
Conclusion:
Awareness and proactive management of OSD in glaucoma patients can significantly improve their treatment experience and quality of life.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.